Allergan Aesthetics, an AbbVie company, announced results from two single-center clinical studies evaluating targeted skincare regimens alone and in combination with DiamondGlow dermabrasion treatments in individuals taking medical weight loss medications, including glucagon-like peptide-1 receptor agonists. The studies, presented at the Science of Skin Summit in Austin, Texas, from Sept. 17-20, 2026, showed statistically significant, investigator-assessed improvements in selected skin quality measures across the face, neck, upper inner arms and distal thighs. The 12-week skincare study included nine participants who completed the study, while the six-week DiamondGlow plus skincare study included 11 participants who completed at least one post-treatment assessment. In the 12-week study, participants reported that facial skin appeared approximately 10 years younger after four weeks of twice-daily growth factor serum use, and in the six-week study, participants reported facial skin appeared approximately 7.5 years younger after three DiamondGlow treatments and six weeks of the topical skincare regimen. Elizabeth Makino, a co-author of both studies and director of clinical development and global scientific affairs for skincare research and development at Allergan Aesthetics, said the early data contribute clinical evidence evaluating these approaches and that additional research in larger populations will help further characterize the findings.
AbbVie IncAbbVie's Allergan Aesthetics reported statistically significant skin quality improvements from its skincare regimens and DiamondGlow treatments in medical weight loss patients.
